Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01666041

Enrollment

120

Registered

2012-08-16

Start date

2012-01-31

Completion date

2013-07-31

Last updated

2014-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertriglyceridemia

Keywords

insulin resistance

Brief summary

The investigators hypothesize that fenofibrate/omega will improve insulin resistance compared with fenofibrate

Interventions

DRUGplacebo

DRUGfenofibrate/omega

DRUGfenofibrate

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

25 Years to 80 Years

Healthy volunteers

Inclusion criteria

* hypertriglyceridemia

Exclusion criteria

* moderate or severe hypertension, uncontrolled diabetes (HbA1c \> 9%), nephrotic syndrome, hypothyroidism, coronary artery disease, or peripheral vascular disease

Design outcomes

Primary

Measure	Time frame
flow-mediated dilation	8 weeks of treatment

Secondary

Measure	Time frame
insulin resistance	8 weeks of treatment

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026